For the quarter ending 2026-03-31, CYCN had -$417K decrease in cash & cash equivalents over the period. -$1,242K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -3,177 | -799 | -976 | -1,753 |
| Gain from settlement of account payable | - | 0 | 0 | - |
| Share-based compensation expense | 58 | 95 | 118 | 228 |
| Accounts receivable | -1,000 | 900 | -425 | -31 |
| Prepaid expenses | -129 | -2 | -76 | 41 |
| Other current assets | 0 | 0 | -16 | 11 |
| Accounts payable | -51 | 28 | 18 | 72 |
| Accrued research and development costs | -50 | 152 | -26 | 20 |
| Accrued expenses and other current liabilities | 915 | -157 | 85 | -17 |
| Net cash used in operating activities | -1,176 | -1,579 | -264 | -1,471 |
| Purchases of property and equipment | 66 | - | - | - |
| Net cash used in investing activities | -66 | - | - | - |
| Proceeds from atm | 825 | 251 | 1,826 | - |
| Proceeds from private placement | - | 0 | 0 | 1,375 |
| Issuance costs paid for private placement | - | 0 | 0 | -130 |
| Net cash provided by financing activities | 825 | 251 | 1,826 | 1,245 |
| Effect of exchange rate changes on cash and cash equivalents | - | 0 | 0 | 0 |
| Net increase (decrease) in cash and cash equivalents | -417 | -1,328 | 1,562 | -226 |
| Cash and cash equivalents, beginning of period | 3,240 | 4,568 | 3,232 | - |
| Cash and cash equivalents, end of period | 2,823 | 3,240 | 4,568 | - |
Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics, Inc. (CYCN)